Substance / Medication

Alendronate sodium

Overview

Clinical overview including description, indications, and evidence base is pending physician authorship or FDA SPL integration. Graph-derived relationship data is available below.

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Menopausal osteoporosis

Postmenopausal osteoporosis

Administration & Protocol

Dosing, route, and treatment protocol

Administration details including route, dosing schedules, preparation instructions, and contraindications are pending physician authorship.

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Research Evidence

Published studies and systematic reviews

Sort:

Bisphosphonates in combination with alendronate sodium increase bone mineral density and modulate IL-6, TNF-α, and IGF-1 in patients with osteoporosis.

Gu Xuechun, Zhang Liyuan, Chen Xiangyi et al. · Int J Clin Pharmacol Ther · 2025

PMID: 40013964RCT

Calcifediol (25-hydroxyvitamin D) improvement and calcium-phosphate metabolism of alendronate sodium/vitamin Dcombination in Chinese women with postmenopausal osteoporosis: a post hoc efficacy analysis and safety reappraisal.

Liao Er-Yuan, Zhang Zhen-Lin, Xia Wei-Bo et al. · BMC Musculoskelet Disord · 2018

PMID: 29970059RCTFull text (PMC)

Pharmacokinetics of coadministration of levothyroxine sodium and alendronate sodium new effervescent formulation.

Bone H G, Walter M A, Hurley M E et al. · Osteoporos Int · 2017

PMID: 28204953RCTFull text (PMC)

Bioequivalence of generic alendronate sodium tablets (70 mg) to Fosamaxtablets (70 mg) in fasting, healthy volunteers: a randomized, open-label, three-way, reference-replicated crossover study.

Zhang Yifan, Chen Xiaoyan, Tang Yunbiao et al. · Drug Des Devel Ther · 2017

PMID: 28744102RCTFull text (PMC)

Bioavailability and bioequivalence of two oral formulations of alendronate sodium 70 mg: an open-label, randomized, two-period crossover comparison in healthy Korean adult male volunteers.

Rhim Si-Youn, Park Jin-Hee, Park Yoo-Sin et al. · Clin Ther · 2009

PMID: 19539104RCT

Hantzsch pre-column derivatization for simultaneous determination of alendronate sodium and its pharmacopoeial related impurity: Comparative study with synchronous fluorometry using fluorescamine.

El-Yazbi Amira F, El-Kimary Eman I, Youssef Rasha M · J Food Drug Anal · 2019

PMID: 30648573ObservationalFull text (PMC)

[Comparison of the clinical effects between Dihuang Decoction and alendronate sodium in the treatment of primary osteoporosis].

Wan Jun-Ming, Zhang Jian-Fang, Huang Kai et al. · Zhongguo Gu Shang · 2019

PMID: 31277537Observational

COMPARATIVE BIOAVAILABILITY ANALYSIS OF ORAL ALENDRONATE SODIUM FORMULATIONS IN PAKISTAN.

Riaz Humayun, Goodman Brian, Bashir Sajid et al. · Acta Pol Pharm · 2016

PMID: 29648726Observational

Alendronate sodium/vitamin D3 combination tablet versus calcitriol for osteoporosis in Chinese postmenopausal women: a 6-month, randomized, open-label, active-comparator-controlled study with a 6-month extension.

Zhang Z L, Liao E Y, Xia W B et al. · Osteoporos Int · 2015

PMID: 25929192ObservationalFull text (PMC)

Comparison of the effects of alendronate sodium and calcitonin on bone-prosthesis osseointegration in osteoporotic rats.

Chen B-L, Xie D-H, Zheng Z-M et al. · Osteoporos Int · 2011

PMID: 20204600Observational

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Risk profile, common and serious adverse effects, contraindications, and drug interactions are pending physician authorship.

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type: Substance / Medication
Fully Specified Name: Alendronate sodium (substance)
SNOMED CT: 391729003
UMLS CUI: C0700482

Clinical Data

This intervention maps to 2 entities in the Ltrl knowledge graph.

Conditions

Biomarkers

Specialists

Symptoms

Data is sourced from SNOMED CT, UMLS, and the Ltrl clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.